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FA at 100 mg/m2 as 2 h infusion on days 1–2, FU at 400 mg/m2 as
bolus on days 1–2 plus FU at 600 mg/m2 as 22 h infusion on days
1–2 (folfiri) every 2 weeks, or arm B: Cpt-11 at 250 mg/m2 on day 1
and xeloda 2000 mg/m2 for 14 days (xeliri) every 3 weeks.
Results: Up to now 91 patients have been enrolled: 54 are evalu-
able for activity and toxicity (A/B: 20/34). The main characteristics
of the evaluable patients are (A/B): median PS: 0/0; sites of dis-
ease: liver 12/26, lung 7/15, lymph-nodes 1/8, others 3/4. Among
the evaluable patients we observed the following responses (A/
B) CR: 1/0 (5/0%), PR: 4/18 (20/53%), SD: 11/11 (55/32%) and PRO:
4/5 (20/15%) for an ORR of 25% and 53%, respectively. Grades 3–4
haematologic toxicity (NCI criteria) were: neutropenia 15/21%
and anaemia 5/3% whilst the main non haematologic side effect
was diarrhoea observed in 5/18%, respectively.
Conclusions: Our preliminary results do not permit any
definitive conclusion regard the activity of the two combinations.
The toxicity profile of xeliri is similar to those of previous
studies.
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Background: The addition of bevacizumab (BEV) to irinotecan
(CPT-11) plus bolus fluorouracil (FU) and folinic acid (FA) (IFL regi-
men) demonstrated to be more active and more effective than che-
motherapy alone in a randomised phase III trial. However IFL is
considered more toxic than FOLFIRI regimen. So we started a
phase II trial to evaluate the activity and the safety of the combina-
tion of BEV plus FOLFIRI as first-line therapy in ACC patients (pts).
Methods: Untreated pts with histologically confirmed diagnosis
of colorectal cancer entered into the trial if they satisfied the fol-
lowing main inclusion criteria: presence of measurable disease,
age > 18 years, performance status 6 2 (ECOG scale), adequate
bone marrow reserve and renal and hepatic function, informed
written consent. An history of cardiovascular disease, thrombo-
embolic events and/or coagulative disorders were considered as
exclusion criteria.
The enrolled pts were treated with CPT-11 at 180 mg/m2 on
day 1, FA at 100 mg/m2 as 2 h infusion on days 1–2, FU at
400 mg/m2 as bolus on days 1–2 and FU at 600 mg/m2 as 22 h infu-
sion on days 1–2 (FOLFIRI) plus BEV at the dosage of 5 mg/kg on
day 1, every two weeks. A maximum of 12 cycles of chemotherapy
was planned and a maintenance with BEV for 6 months was per-
mitted. The evaluation of the activity (recist criteria) was per-
formed every four cycles.
Results: Up to now 72 pts have been enrolled and 61 are evalu-
able for activity and safety (eleven pts are too early). The main
characteristics of the evaluable pts were M/F: 32/29; median PS:
0 (range 0–2); median age 61 (range 33–73); primary site (colon/
rectum): 40/21; main sites of disease: liver 45, lung 16, lymph-
nodes 15, others 6; single site: 39 and multiple sites: 22.
Three CR (5%) and 25 PR (41%) were observed for an ORR of 46%;
26 pts had SD (43%) for an overall TGCR of 89%. Only 7 PRO (11%)
were observed. The response rate according to site were: liver
21/45 (46.6%), lung 8/16 (50%). The only grades 3–4 toxicity (NCI cri-
teria) were neutropenia 10% and thrombocytopenia 2%. Ten pts
(16%) had hypertension but only one was uncontrolled by medical
therapy and interrupted the study. One pts had epistaxis.
Conclusions: Our results indicate that the addition of BEV to
FOLFIRI regimen is an active and well tolerated first-line treat-
ment for ACC pts. Final data will be available for the meeting.
doi:10.1016/j.ejcsup.2008.06.042
RADIOCHEMOTHERAPY FOR ANAL CARCINOMA: OUR
EXPERIENCE
F. Morelli, A. Raguso, A. Piano, M. Troiano, G. Palomba, L. Nanni,
M. Di Bisceglie, S. Parisi, E. Maiello. Oncology Unit, Radiotherapy
Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG),
Italy.
Background: Radiochemotherapy of anal carcinoma is an organ
sparing approach with a high curative potential.
Patients and methods: Between August 1999 and June 2007, 18
patients were treated with external radiation therapy (RT) and
concomitant chemotherapy (CT). The main characteristics of
patients were: histology: 14 squamous carcinoma, 2 basaloid, 1
adenocarcinoma, 1 undifferentiated carcinoma; stage (2001 UICC
classification): II 7 cases, III A 9, III B 2; age: median 61 year, range
33–79; sex (F/M): 10/8. RT was delivered at the whole pelvis with a
four-field box technique followed by a boost at the primary
tumour. The median dose of RT at the whole pelvis and at the pri-
mary tumours was 45 Gy and 55 Gy, respectively. CT was carried
out during the first and last four days of RTwith continuous infu-
sion of 5-fluorouracil (1000 mg/m2/day) plus bolus mitomycin C
(10 mg/m2 on day 1) in 16 patients or cisplatin (100 mg/m2) in 2.
After a rest period of 4-6 weeks two courses of cisplatin plus 5-
Fluorouracil was delivered in 4 patients with locoregional
advanced disease.
Results: CR were observed in 8 patients (44%), PR in 4 (22%), SD
in 4, and PD in 2. Local recurrences occurred in 4 patients previ-
ously obtaining RC (1/8), RP (2/4), SD (1/4) and 2 of them were res-
cued by conservative surgery. Distant metastases occurred in two
cases and inguinal failure in one. The median duration of
response was 12 months (3–62) and the sphincter preservation
rate was 90% (16 patients). Temporary interrumption of the treat-
ment as a result of acute toxicity (gastrointestinal) was necessary
in 3 patients. With a median follow up of 17 months (range 5–57),
10 patients are alive and 9 disease-free. Eight patients died due to
a progressive disease (locoregional failure in 5 patients, liver
metastases in 2, lung metastases in 1).
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